ASH 2018 | CAR T-cell updates in lymphoma and myeloma from ASH 2018
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, shares her views on the latest real world data on CAR T-cell therapy presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. This includes how axicabtagene ciloleucel transitions from clinical trials into real world practice, the emergence of CD30 as a target, and the surge in CAR T-cell research in China. In the multiple myeloma space, the anti-BCMA CAR T-cell product LCAR-B38M is under investigation (LEGEND-2; NCT03090659).
Get great new content delivered to your inboxSign up